Market Place
Sourcing Support
Outlook Therapeutics Finalizes $5.0M Direct Offering Close
23 Apr 2026 //
FIRSTWORD PHARMA
Outlook Therapeutics Prices $5M Public Offering
24 Mar 2026 //
GLOBENEWSWIRE
Outlook Therapeutics Names Cantrell VP of Corporate Strategy
06 Jan 2026 //
GLOBENEWSWIRE
Outlook Therapeutics Reports Q3 Fy2025 Results, Gives Corporate
14 Aug 2025 //
GLOBENEWSWIRE
Outlook Therapeutics Joins Virtual Investor Summer Conference
22 Jul 2025 //
GLOBENEWSWIRE
Outlook Therapeutics Names Bob Jahr CEO
01 Jul 2025 //
GLOBENEWSWIRE
Outlook Therapeutics Joins Virtual Investor Lunch Event
18 Jun 2025 //
GLOBENEWSWIRE
Outlook Therapeutics Prices $13.0M Public Offering
23 May 2025 //
GLOBENEWSWIRE
Outlook Therapeutics Plans Public Offering of Stock and Warrants
22 May 2025 //
GLOBENEWSWIRE
Outlook Therapeutics Reports Q2 Fiscal Year 2025 Results
15 May 2025 //
GLOBENEWSWIRE
Outlook Therapeutics Reports Q1 FY25 Financial, Corporate Update
14 Feb 2025 //
GLOBENEWSWIRE
Outlook Therapeutics Joins Virtual Investor “What This Means”
04 Feb 2025 //
GLOBENEWSWIRE
Outlook Appoints Faisal as Chairman of Board of Directors
31 Jan 2025 //
GLOBENEWSWIRE
Outlook Shows Norse Eight Results For Wet AMD Treatment ONS-5010
23 Jan 2025 //
GLOBENEWSWIRE
Outlook Therapeutic To Present At LIVE! with Webull Connect Webinar
22 Jan 2025 //
GLOBENEWSWIRE
Outlook Therapeutics Reports NORSE EIGHT Trial Efficacy And Safety
16 Jan 2025 //
GLOBENEWSWIRE
Outlook Therapeutics Joins Investor `What This Means` Segment
08 Jan 2025 //
GLOBENEWSWIRE
Outlook Therapeutics Reports 2024 Financial Results
27 Dec 2024 //
GLOBENEWSWIRE
Outlook lays off 23% of staff as it eyes FDA approval, EU debut
16 Dec 2024 //
FIERCE BIOTECH
Outlook Therapeutics® Announces Executive Leadership Transition
03 Dec 2024 //
GLOBENEWSWIRE
Outlook Therapeutics Announces Preliminary Norse eight Results
27 Nov 2024 //
GLOBENEWSWIRE
Outlook Therapeutics to Present at Guggenheim Healthcare Conference
06 Nov 2024 //
GLOBENEWSWIRE
Outlook Therapeutics® Joins Virtual Investor CEO Connect Segment
17 Oct 2024 //
GLOBENEWSWIRE
Outlook Therapeutics To Join Virtual Investor Closing Bell
16 Sep 2024 //
GLOBENEWSWIRE
Outlook Therapeutics to Present at H.C. Wainwright Global Conference
03 Sep 2024 //
GLOBENEWSWIRE
Outlook Therapeutics To Present At H.C. Wainwright Conference
12 Aug 2024 //
GLOBENEWSWIRE
Outlook Therapeutics To Report Q3 FY 2024 Results On August 14
07 Aug 2024 //
GLOBENEWSWIRE
Outlook Therapeutics® to Present at the Virtual Investor Pitch Conference
11 Jun 2024 //
GLOBENEWSWIRE
Outlook Therapeutics Submits UK MAA For ONS-5010 As Wet AMD Treatment
13 May 2024 //
GLOBENEWSWIRE
Outlook Therapeutics Q2 FY2024 Results On May 16
09 May 2024 //
GLOBENEWSWIRE
Outlook Therapeutics® to Present at the Retina World Congress 2024
02 May 2024 //
GLOBENEWSWIRE
Outlook Therapeutics® at OIS Retina Innovation Showcase
29 Apr 2024 //
GLOBENEWSWIRE
Outlook Therapeutics® $5M Private Placement Closing
15 Apr 2024 //
GLOBENEWSWIRE
Outlook® Receives European Union Positive CHMP Opinion for ONS-5010
22 Mar 2024 //
GLOBENEWSWIRE
Outlook Therapeutics® Announces Closing of Private Placement of up to $159M
18 Mar 2024 //
GLOBENEWSWIRE
Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split
12 Mar 2024 //
GLOBENEWSWIRE
Outlook Therapeutics Receives FDA Agreement Under SPA for Study, NORSE EIGHT
23 Jan 2024 //
GLOBENEWSWIRE
Outlook Therapeutics® Announces Strategic Organizational Realignment
06 Dec 2023 //
GLOBENEWSWIRE
Outlook Adds Expertise with Appointment of Jedd Comiskey as Senior VP
14 Nov 2023 //
GLOBENEWSWIRE
Outlook Therapeutics® Provides Update on Type A Meetings with FDA
02 Nov 2023 //
GLOBENEWSWIRE
Outlook Therapeutics® to Present at Guggenheim™s 5th Annual INI Conference
01 Nov 2023 //
GLOBENEWSWIRE
Outlook Therapeutics® Requests Type A Meeting With FDA
29 Sep 2023 //
GLOBENEWSWIRE
Outlook to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
21 Sep 2023 //
GLOBENEWSWIRE
Outlook to Present at H.C. Wainwright 25th Annual Global Investment Conference
05 Sep 2023 //
GLOBENEWSWIRE
Outlook Therapeutics® to Present at BTIG Virtual Biotechnology Conference 2023
01 Aug 2023 //
GLOBENEWSWIRE
Outlook Therapeutics to Present at the H.C. Wainwright BioConnect Conference
27 Apr 2023 //
GLOBENEWSWIRE
Outlook Therapeutics® Confirms It Has No Exposure to Silicon Valley Bank
13 Mar 2023 //
GLOBENEWSWIRE
Outlook Therapeutics Reports Financial Results for Q1 Fiscal Year 2023
14 Feb 2023 //
GLOBENEWSWIRE
Outlook to Present at the SVB Securities Global Biopharma Conference
07 Feb 2023 //
GLOBENEWSWIRE
Outlook Therapeutics Appoints Surendra Sharma as Senior Vice President
19 Jan 2023 //
GLOBENEWSWIRE
Outlook to Present at the Virtual Investor 2023 Companies to Watch Event
09 Jan 2023 //
GLOBENEWSWIRE
Outlook Therapeutics Announces $25 M Registered Direct Offering
23 Dec 2022 //
GLOBENEWSWIRE
Outlook Therapeutics® Enters Definitive Agreement for $31.8 M Convertible Note
23 Dec 2022 //
GLOBENEWSWIRE
Outlook Therapeutics® Announces Validation of MAA by theEMA for ONS-5010
22 Dec 2022 //
PRESS RELEASE
Outlook Therapeutics® Announces Validation of MAA by the EMA for ONS-5010
22 Dec 2022 //
GLOBENEWSWIRE
Outlook Therapeutics to Participate in Cantor Fitzgerald Medical & Aesthetic
01 Dec 2022 //
GLOBENEWSWIRE
Outlook Therapeutics to Present at the BTIG Ophthalmology Day
22 Nov 2022 //
GLOBENEWSWIRE
Outlook Announces Acceptance of Biologics License Application byFDA for ONS-5010
28 Oct 2022 //
GLOBENEWSWIRE
Outlook ®and AmerisourceBergen Announce Strategic Agreement for ONS-5010
27 Sep 2022 //
GLOBENEWSWIRE
Outlook Therapeutics® to Present at the H.C. Wainwright 24th Annual GIC
07 Sep 2022 //
GLOBENEWSWIRE
